Cargando…

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Targeted delivery of compounds to particular cell subsets can enhance therapeutic index by concentrating their action on the cells of interest. Because attempts to target tumors directly have yielded limited benefit, we instead target endogenous immune cell subsets in the circulation that can migrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmid, Daniela, Park, Chun Gwon, Hartl, Christina A., Subedi, Nikita, Cartwright, Adam N., Puerto, Regina Bou, Zheng, Yiran, Maiarana, James, Freeman, Gordon J., Wucherpfennig, Kai W., Irvine, Darrell J., Goldberg, Michael S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700944/ https://www.ncbi.nlm.nih.gov/pubmed/29170511 http://dx.doi.org/10.1038/s41467-017-01830-8

Ejemplares similares

T lymphocyte engineering with cytokine nanogels for enhanced cancer immunotherapy
por: Tang, Li, et al.
Publicado: (2015)

Systemic delivery of liposome-anchored anti-CD137 and IL2-Fc prevents lethal toxicity and elicits potent antitumor immunity
por: Zhang, Yuan, et al.
Publicado: (2015)

Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles
por: Su, Xingfang, et al.
Publicado: (2013)

Membrane Anchored Immunostimulatory Oligonucleotides for In Vivo Cell Modification and Localized Immunotherapy**
por: Liu, Haipeng, et al.
Publicado: (2011)

Engineering autoreactive T and B cell responses toward active immunotherapy for inflammatory diseases
por: Chang, Jason Y. H., et al.
Publicado: (2021)

Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer
por: Hartl, Christina A., et al.
Publicado: (2019)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

CRISPR-Mediated Editing of the B Cell Receptor in Primary Human B Cells
por: Greiner, Vera, et al.
Publicado: (2019)

Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy
por: Zhao, Bonan, et al.
Publicado: (2022)

Novel Cancer Immunotherapies and Antitumor Immunity
por: Zhao, Lei, et al.
Publicado: (2019)

IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells
por: Lu, Zeyu, et al.
Publicado: (2021)

In vitro evolution of enhanced RNA replicons for immunotherapy
por: Li, Yingzhong, et al.
Publicado: (2019)

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
por: Dai, Enyong, et al.
Publicado: (2021)

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity
por: Seya, Tsukasa, et al.
Publicado: (2015)

T-lymphocytes from focused ultrasound ablation subsequently mediate cellular antitumor immunity after adoptive cell transfer immunotherapy
por: Ran, Li-Feng, et al.
Publicado: (2023)

Nuclear receptor LXRβ controls fitness and functionality of activated T cells
por: Michaels, Anthony J., et al.
Publicado: (2020)

Harnessing the antitumor potential of macrophages for cancer immunotherapy
por: Long, Kristen B, et al.
Publicado: (2013)

Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy
por: Li, Bo, et al.
Publicado: (2021)

Focused ultrasound and immunotherapy
por: Hurwitz, Mark
Publicado: (2015)

Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy
por: Yang, Yang, et al.
Publicado: (2023)

Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice
por: Kang, Byong H., et al.
Publicado: (2021)

The Assembly of Diverse Immune Receptors Is Focused on a Polar Membrane-Embedded Interaction Site
por: Feng, Jianwen, et al.
Publicado: (2006)

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
por: Bhagchandani, Sachin, et al.
Publicado: (2021)

Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
por: Schaaf, Marco B., et al.
Publicado: (2018)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Xing, Rui, et al.
Publicado: (2021)

Harnessing Antitumor CD4(+) T Cells for Cancer Immunotherapy
por: Ben Khelil, Myriam, et al.
Publicado: (2022)

Perspectives on Recent Progress in Focused Ultrasound Immunotherapy
por: Sheybani, Natasha D., et al.
Publicado: (2019)

Antitumor therapy for breast cancer: Focus on tumor‐associated macrophages and nanosized drug delivery systems
por: Zhan, Cuiping, et al.
Publicado: (2023)

Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies
por: Shevtsov, Maxim, et al.
Publicado: (2016)

KALRN mutations promote antitumor immunity and immunotherapy response in cancer
por: Li, Mengyuan, et al.
Publicado: (2020)

Tumor Immune Microenvironments (TIMEs): Responsive Nanoplatforms for Antitumor Immunotherapy
por: Sui, Xueqing, et al.
Publicado: (2020)

Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity
por: Liang, Jingjing, et al.
Publicado: (2020)

Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies
por: Hussain, Khiyam, et al.
Publicado: (2021)

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
por: Veltman, Joris D., et al.
Publicado: (2010)

Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity
por: Perry, Curtis J., et al.
Publicado: (2018)

Editorial of special focus on melanoma immunotherapy
por: Rossi, Ernesto
Publicado: (2022)

Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies
por: Lutz, Emi A., et al.
Publicado: (2022)

Antigen Delivery by Lipid-Enveloped PLGA Microparticle Vaccines Mediated by in Situ Vesicle Shedding
por: Hanson, Melissa C., et al.
Publicado: (2014)

TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations
por: Chhabra, Arvind
Publicado: (2011)

Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy
por: Zheng, Xiaobo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f10o2d8ilhei14a6octchvn313